DiscoverBiotech 2050 PodcastGene Mack, Interim CEO & CFO of Gain Therapeutics: Leading the Charge in Parkinson's Breakthroughs
Gene Mack, Interim CEO & CFO of Gain Therapeutics: Leading the Charge in Parkinson's Breakthroughs

Gene Mack, Interim CEO & CFO of Gain Therapeutics: Leading the Charge in Parkinson's Breakthroughs

Update: 2024-10-30
Share

Description

Biotech2050 Host, Rahul Chaturvedi, engages with Gene Mack, Interim CEO and CFO of Gain Therapeutics, as he shares his journey from aspiring neurosurgeon to biotech leader. Gene reflects on his career shift from clinical research to Wall Street and eventually operational roles in biotech. He details the development of Gain's lead asset, GT02287, which targets Parkinson's disease by aiming for disease modification rather than symptom management. Gene also discusses the challenges of biotech leadership, running clinical trials, and navigating the financial landscape, highlighting the dynamic intersection of science, business, and innovation in neurodegenerative diseases.
Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Gene Mack, Interim CEO & CFO of Gain Therapeutics: Leading the Charge in Parkinson's Breakthroughs

Gene Mack, Interim CEO & CFO of Gain Therapeutics: Leading the Charge in Parkinson's Breakthroughs

Biotech 2050